<?xml version="1.0" encoding="UTF-8"?>
<p>Platelet cell membranes, and atherosclerotic plaques, have both CB
 <sub>1</sub> and CB
 <sub>2</sub>.
 <sup>[
  <xref rid="R4" ref-type="bibr">4</xref>]
 </sup> Low-dose oral THC inhibits atherosclerosis progression via pleiotropic immunomodulatory effects in apolipoprotein-E knockout models,
 <sup>[
  <xref rid="R9" ref-type="bibr">9</xref>]
 </sup> as well as inhibiting lymphoid proliferation and macrophage chemotaxis, in a dose-dependent manner.
 <sup>[
  <xref rid="R4" ref-type="bibr">4</xref>,
  <xref rid="R9" ref-type="bibr">9</xref>]
 </sup> This effect can also be inhibited by a CB
 <sub>2</sub> antagonist.
 <sup>[
  <xref rid="R4" ref-type="bibr">4</xref>]
 </sup> A similar function was observed for CB
 <sub>2</sub> in vascular smooth muscle cells in coronary arteries. Depending on receptor activation, the ECS can promote destruction of plaques; a potential druggable target.
</p>
